<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153071">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942590</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00043680</org_study_id>
    <secondary_id>R01 FD004364</secondary_id>
    <nct_id>NCT01942590</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy</brief_title>
  <official_title>A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dwight Koeberl, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source- FDA OOPD

      The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor
      function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme
      replacement therapy (ERT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in CK reflecting worsening of muscle involvement</measure>
    <time_frame>Baseline, week 12, week 18, and week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Worsening muscle involvement, as defined by &gt;3x increase in CK from baseline that is &gt;2x the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in AST, ALT, and bilirubin representing liver toxicity</measure>
    <time_frame>Baseline, week 12, week 18, and week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Liver toxicity, as defined by a &gt;3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of &gt;3x the upper limit of normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change 6 minute walk test</measure>
    <time_frame>Baseline, Weeks 6, 12, 18 and 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess exercise tolerance in study patients; test administered by physical therapist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity in pulmonary function testing</measure>
    <time_frame>Baseline, Weeks 18 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Clenbuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially, 40 mcg each morning for one week.  Then, increase to 40 mcg  BID for the next 5 weeks.  If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week.  Then, last dose increase will be 80 mcg BID until week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenbuterol</intervention_name>
    <arm_group_label>Clenbuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Pompe disease by blood acid alpha-glucosidase assay and acid
             alpha-glucosidase gene sequencing,

          2. Age: 18+ years at enrollment,

          3. Receiving ERT at standard dose (20 mg/kg every 2 weeks) for at least 52 weeks,

          4. Subjects are capable of giving written consent.

        Exclusion Criteria:

          1. Continuous invasive ventilation (via tracheostomy or endotracheal tube)

          2. Clinically relevant illness within two weeks of enrollment including fever &gt; 38.2 C,
             vomiting more than once in 24 hours, seizure, or other symptom deemed
             contraindicative to new therapy.

          3. Chronic heart disease (Myocardial infarction, arrythmia, cardiomyopathy)

          4. Tachycardia

          5. History of seizure disorder

          6. Hyperthyroidism

          7. Pheochromocytoma

          8. Pregnancy

          9. History of diabetes

         10. History of hypersensitivity to beta 2-agonist drugs such as albuterol, levalbuterol
             (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol
             (Serevent),

         11. Patients on a non-standard schedule for ERT; for example, weekly infusions as opposed
             to infusions every two weeks.

         12. Treatment for asthma in the previous 12 months.

         13. The use of the following concommitant meds is prohibited during the study:

               -  diuretics (water pill);

               -  digoxin (digitalis, Lanoxin);

               -  beta-blockers such as atenolol (Tenormin), metoprolol (Lopressor), and
                  propranolol (Inderal);

               -  tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin
                  (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor);

               -  Monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine
                  (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine
                  (Parnate); or

               -  other bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol
                  (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol
                  (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or
                  isoproterenol (Isuprel Mistometer).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight D Koeberl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crista K Walters, MS, PNP-BC</last_name>
    <phone>919-681-1945</phone>
    <email>crista.walters@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dwight D Koeberl, MD, PhD</last_name>
    <phone>919-684-2036</phone>
    <email>dwight.koeberl@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crista K Walters, MS, PNP-BC</last_name>
      <phone>919-681-1945</phone>
      <email>crista.walters@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dwight D Koeberl, MD, PhD</last_name>
      <phone>919-684-2036</phone>
      <email>koebe001@mc.duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dwight D Koeberl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kamalakkannan G, Petrilli CM, George I, LaManca J, McLaughlin BT, Shane E, Mancini DM, Maybaum S. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant. 2008 Apr;27(4):457-61. doi: 10.1016/j.healun.2008.01.013.</citation>
    <PMID>18374884</PMID>
  </reference>
  <reference>
    <citation>Koeberl DD, Luo X, Sun B, McVie-Wylie A, Dai J, Li S, Banugaria SG, Chen YT, Bali DS. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab. 2011 Jun;103(2):107-12. doi: 10.1016/j.ymgme.2011.02.006. Epub 2011 Feb 13.</citation>
    <PMID>21397538</PMID>
  </reference>
  <reference>
    <citation>Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. Î²2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab. 2012 Feb;105(2):221-7. doi: 10.1016/j.ymgme.2011.11.005. Epub 2011 Nov 11.</citation>
    <PMID>22154081</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Dwight Koeberl, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pompe disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clenbuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
